Kinetics of Nevirapine and Its Impact on HIV-1 RNA Levels in Maternal Plasma and Breast Milk Over Time After Perinatal Single-Dose Nevirapine

Simple item page
dc.contributor.authorAizire, Jim
dc.contributor.authorMcConnell, Michelle S.
dc.contributor.authorMudiope, Peter
dc.contributor.authorMubiru, Michael
dc.contributor.authorMatovu, Flavia
dc.contributor.authorParsons, Teresa L.
dc.contributor.authorElbireer, Ali ,
dc.contributor.authorNolan, Monica
dc.contributor.authorJanoff, Edward N.
dc.contributor.authorGlenn Fowler, Mary
dc.date.accessioned2023-06-21T02:03:20Z
dc.date.available2023-06-21T02:03:20Z
dc.date.issued2012
dc.description.abstractTo determine kinetics after single-dose nevirapine and the impact on HIV RNA [viral load (VL)] in maternal plasma and breast milk (BM). Methods: Cohort of 120 HIV-1–infected pregnant Ugandan women received perinatal single-dose nevirapine alone and followed up with their infants through 24 weeks postdelivery. We assessed the relationship of nevirapine concentration (tandem mass spectroscopy) and HIV-1 VL (Roche AMPLICOR HIV-1 Kit, version 1.5) in maternal plasma and BM over time. Results: At week 1 postpartum, NVP ($10 ng/mL) was detected in all 53 plasma and 47 of 51 (92.2%) BM samples with median (inter- quartile ranges) of, respectively, 171 (78–214) ng/mL and 112 (64–158) ng/mL, P = 0.075, which decreased subsequently with traces persisting through week 4 in plasma. Plasma and BM VL dropped by week 1 and were highly correlated at delivery (R = 0.71, P , 0.001) and week 1 (R = 0.69, P , 0.001) but not thereafter. At week 1, VL correlated inversely with NVP concentra- tion in plasma (R = 0.39, P = 0.004) and BM (R = 0.48, P = 0.013). There was a VL rebound in both compartments, which peaked at week 4 to levels greater than those at week 1 [significantly in plasma (P , 0.001) but not in BM] and remained stable thereafter. Median VL was consistently greater (11- to 50-fold) in plasma than BM at all time points (all P , 0.001). Conclusions: After single-dose nevirapine, NVP concentration was comparably high through week 1, accompanied by suppression of plasma and BM VL. A longer “tail” (.1 week) of potent postnatal antiretroviral drugs is warranted to minimize the observed VL rebound and potential for NVP resistance as a result of persistent NVP tracesen_US
dc.identifier.citationAizire, J., McConnell, M. S., Mudiope, P., Mubiru, M., Matovu, F., Parsons, T. L., ... & Fowler, M. G. (2012). Kinetics of nevirapine and its impact on HIV-1 RNA levels in maternal plasma and breast milk over time after perinatal single-dose nevirapine. JAIDS Journal of Acquired Immune Deficiency Syndromes, 60(5), 483-488.en_US
dc.identifier.urihttps://journals.lww.com/jaids/fulltext/2012/08150/Kinetics_of_Nevirapine_and_Its_Impact_on_HIV_1_RNA.6.aspx
dc.identifier.urihttps://nru.uncst.go.ug/handle/123456789/8955
dc.language.isoenen_US
dc.publisherJAIDS Journal of Acquired Immune Deficiency Syndromesen_US
dc.subjectNevirapineen_US
dc.subjectHIV-1 RNAen_US
dc.subjectMaternal plasmaen_US
dc.subjectBreast milken_US
dc.titleKinetics of Nevirapine and Its Impact on HIV-1 RNA Levels in Maternal Plasma and Breast Milk Over Time After Perinatal Single-Dose Nevirapineen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Kinetics of Nevirapine and Its Impact on HIV-1 RNA Levels.pdf
Size:
267.16 KB
Format:
Adobe Portable Document Format
Description:
Article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences